In prostate cancer an increased number of holoclones is associated with the expression of the putative stem cell markers CD44, integrin α2β1, CD133 [14], [17], PSAlo expression [23] and aldehyde dehydrogenase 1 (ALDH) activity [20]. The gene discussed is CD44; the disease is prostate carcinoma.